Tempus
- Market Valuation$5 B2020-03-13
- Total Funding$620 M
OverviewSuggest Edit
Tempus Labs is a genomics and data-analytics company. It works with doctors and patients to use genomic data to more effectively choose treatment options based on outcomes from other patients.
| Type | Private | |
| Founded | 2015 | |
| HQ | Chicago, IL, US | Map |
| Website | tempus.com | |
| Employee Ratings |
Recent NewsAll News
- Kinnate Biopharma Inc. Presents Data from its Real-World Clinico-Genomic Study Collaboration with Tempus at the Virtual ESMO Targeted Anticancer Therapies Congress
- ProSymmetry Expands Its Lead in Resource Portfolio Management by Launching Tempus Insight+
- Tempus, Groupon Co-Founder's Medical Technically Startup, Is Exploring an IPO
- Rain Therapeutics Announces Collaboration with Tempus for Genomic Analysis in Planned MDM2-Amplified Phase 2 Basket Trial of RAIN-32
Key People/Management at Tempus
Eric Lefkofsky
Founder, CEO
Shane Colley
Chief Technology Officer
Joel Dudley
Chief Scientific Officer
Jim Rogers
Chief Financial Officer
Colette Freeman
Chief People Officer
Ryan Fukushima
Chief Operating Officer
Tempus Office Locations
Tempus has an office in Chicago
Chicago, IL, US (HQ)
600 W Chicago Ave #510
Tempus Financials and Metrics
Summary Metrics
Founding Date | 2015 |
Tempus total Funding | $620 m |
Tempus latest funding size | $100 m |
Time since last funding | 2 years ago |
Tempus investors | New Enterprise Associates, T. Rowe Price, Baillie Gifford, Revolution Growth, Franklin Templeton, Novo Holdings, Baillie Gifford & Co., Kinship Trust Company |
Tempus's latest funding round in March 2020 was reported to be $100 m. In total, Tempus has raised $620 m. Tempus's latest valuation is reported to be $5 b.
Tempus Revenue
Market valuation | 5.0b |
- Source: Crunchbase News - Mar 2020
Tempus Acquisitions / Subsidiaries
| Company Name | Date | Deal Size |
|---|---|---|
| AKESOgen | December 11, 2019 |
Tempus Cybersecurity Score
Tempus Online and Social Media Presence
4.95k Twitter followers
Tempus has 4.95k Twitter Followers. The number of followers has increased 1.1% month over month and increased 3.5% quarter over quarter
Tempus's Trends
Twitter Engagement Stats for @tempuslabs
452
Tweets
963
Following
4.9k
Followers
13
Tweets last 30 days
8.7
Avg. likes per Tweet
100%
Tweets with engagement
Tempus News and Updates
March 07, 2022
Kinnate Biopharma Inc. Presents Data from its Real-World Clinico-Genomic Study Collaboration with Tempus at the Virtual ESMO Targeted Anticancer Therapies Congress
Findings highlight the unmet medical need among cancer patients with BRAF Class II and Class III alterations who may not have access to approved targeted therapies
November 02, 2021
Tempus, Groupon Co-Founder's Medical Technically Startup, Is Exploring an IPO
Tempus, Groupon Co-Founder's Medical Startup, Is Exploring an IPO
June 03, 2021
Rain Therapeutics Announces Collaboration with Tempus for Genomic Analysis in Planned MDM2-Amplified Phase 2 Basket Trial of RAIN-32
Clinical trial for MDM2 amplified cancers expected to commence in second half of 2021 Clinical trial for MDM2 amplified cancers expected to commence in second half of 2021
February 25, 2021
Zentalis Pharmaceuticals and Tempus Announce Strategic Collaboration to Advance Research and Development Capabilities
Tempus’ platform will be used to further evaluate the DNA damage response pathway of Zentalis’ WEE1 inhibitor, ZN-c3, and potential future candidates Tempus’ platform will be used to further evaluate the DNA damage response pathway of Zentalis’ WEE1 inhibitor, ZN-c3, and potential future candidates
February 23, 2021
Tempus Resource by ProSymmetry Now Available on Carahsoft SEWP V and NASPO Contracts
Powerful Resource Management Solutions Now Available to Government Agencies Powerful Resource Management Solutions Now Available to Government Agencies
Tempus Blogs
May 26, 2022
Fortune Brainstorm Health Conference 2020 | Patients First: Transforming Care Through Disruptive Technology
Eric Lefkofsky and Dr. David Agus discuss how Tempus is leveraging data and AI to advance personalized patient care and therapeutic discovery. Video linked here.
The post Fortune Brainstorm Health Conference 2020 | Patients First: Transforming Care Through Disruptive Technology appeared first on Tem…
May 25, 2022
Tempus and Geisinger Find ECG-Based AI Model Can Predict Undiagnosed Structural Heart Disease
Published in Circulation, the rECHOmmend study expands on AI-focused research to improve patient outcomes in cardiology A team of clinicians and scientists from Tempus and Geisinger have found that a new artificial intelligence model can accurately identify patients at increased risk of undiagnose…
May 20, 2022
Prevalence of Germline Findings Among Tumors From Cancer Types Lacking Hereditary Testing Guidelines
Importance: Germline testing guidelines are suggested for specific disease types or a family history of cancer, yet alterations are found in cancer types in which germline testing is not routinely indicated. The clinical role of identifying germline variants in these populations is valuable to patie…
May 20, 2022
Tempus Launches Psychiatric Real-World Data Program to Advance Personalized Medicine
Tempus, a leader in artificial intelligence and precision medicine, today announced the launch of Tempus N+, a program that aims to power precision medicine solutions through the use of real-world data for mental health. Tempus is collaborating with academic medical institutions around the country t…
May 18, 2022
Protocol for Drug Screening of Patient-Derived Tumor Organoids Using High-Content Fluorescent Imaging
Summary High-content imaging of tumor organoids (TOs) treated with therapeutic agents provides detailed cell viability readouts at the organoid level. In contrast, most used protocols provide one number per well. While requiring the use of inverted microscopy with an automated stage, this protocol c…
May 11, 2022
Precision Health Diagnostic and Surveillance Network Uses S Gene Target Failure (SGTF) Combined With Sequencing Technologies to Track Emerging SARS-CoV-2 Variants
Introduction The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic revealed a worldwide lack of effective molecular surveillance networks at local, state, and national levels, which are essential to identify, monitor, and limit viral community spread. SARS-CoV-2 variants of conce…
Tempus Frequently Asked Questions
When was Tempus founded?
Tempus was founded in 2015.
Who are Tempus key executives?
Tempus's key executives are Eric Lefkofsky, Shane Colley and Joel Dudley.
How many employees does Tempus have?
Tempus has 1,549 employees.
Who are Tempus competitors?
Competitors of Tempus include PathAI, Prognos Health and Genomic Health.
Where is Tempus headquarters?
Tempus headquarters is located at 600 W Chicago Ave #510, Chicago.
Where are Tempus offices?
Tempus has an office in Chicago.
How many offices does Tempus have?
Tempus has 1 office.
Learn about Craft real-time company insights
Receive alerts for 300+ data fields across thousands of companies